Thrombosis in pregnancy and cancer

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Pregnancy-associated VTE can occur in any trimester, but daily risk is highest postpartum. DVT is often proximal, left-sided and pelvic. Do not attribute unilateral whole-leg swelling, buttock pain, sudden dyspnoea or syncope to normal pregnancy. Compression ultrasound is first-line for suspected DVT; if negative but clinical suspicion persists, repeat or image iliac veins. Chest X-ray guides suspected PE imaging. V/Q scanning or CTPA are both acceptable according to X-ray, availability and local expertise; explain the small and different maternal and fetal radiation exposures without allowing fear to prevent diagnosis.

Start therapeutic LMWH when VTE is suspected and diagnostic delay is expected, unless bleeding or imminent delivery makes this unsafe. Enoxaparin 1 mg/kg SC every 12 hours is a commonly used exact regimen based on early-pregnancy or current weight according to protocol; some obstetric protocols permit once-daily LMWH for selected patients. Routine anti-Xa monitoring is unnecessary but may be used at extremes of weight, renal impairment or recurrent thrombosis. UFH is an alternative when rapid reversal is important, severe renal failure exists or delivery or intervention is imminent.

Coordinate delivery early. A woman on therapeutic LMWH should avoid further injections once labour begins or membranes rupture and contact the maternity unit. Planned induction or caesarean allows a timed last dose; neuraxial anaesthesia generally requires at least 24 hours after a therapeutic LMWH dose, with longer or different rules for renal impairment and specific agents. Restart depends on haemostasis, delivery type, neuraxial catheter removal and haemorrhage risk. Continue through at least 6 weeks postpartum and a minimum of 3 months total. Warfarin can be used postpartum during breastfeeding; DOAC transfer into milk and limited infant evidence make them unsuitable routinely.

Treat active cancer-associated proximal DVT or PE for 3–6 months and reassess. Continued active cancer, systemic treatment, residual disease or recurrence often supports extension, whereas remission, high bleeding risk and limited benefit may support withdrawal. Review at every treatment transition rather than writing indefinite. If thrombosis recurs, confirm adherence, dose, absorption and imaging; distinguish progression from chronic residual clot; review HIT and APS when relevant. Specialist options include switching oral therapy to therapeutic LMWH or increasing LMWH within a protocol, not empiric combinations.

Specialist cancer care must also integrate platelet trend, procedure timing, catheter need, incidental clot certainty and temporary filter retrieval; the dedicated pathways below preserve these decisions without applying one threshold to every patient.

Key points

Pregnancy and cancer raise VTE probability but symptoms still require objective imaging; do not use D-dimer or a non-validated score alone to dismiss a clinically suspected event.
Therapeutic LMWH is first-line treatment for most pregnancy-associated DVT or PE because it does not cross the placenta and has extensive obstetric experience.
Continue pregnancy-associated VTE treatment for the remainder of pregnancy and at least 6 weeks postpartum, with at least 3 months total therapy.
Warfarin and DOACs are generally avoided for treating VTE during pregnancy; warfarin is compatible with breastfeeding, whereas DOACs are not routinely recommended during breastfeeding.
Plan delivery and neuraxial timing jointly: therapeutic LMWH is normally withheld for at least 24 hours before planned neuraxial procedures, with exact timing set by obstetric anaesthesia protocol.
For active cancer-associated proximal DVT or PE, NICE recommends anticoagulation for 3–6 months then review; continue beyond this while cancer activity, treatment and recurrence risk justify it.
Apixaban or rivaroxaban is an option for many adults with active cancer, but gastrointestinal or genitourinary lesions, interactions, vomiting, organ dysfunction and bleeding can favour LMWH.
Thrombocytopenia requires specialist intensity and transfusion decisions based on clot acuity, location, platelet trend and bleeding; do not use a universal unsupervised platelet cutoff.
A functioning, well-positioned and uninfected catheter associated with thrombosis can often remain while therapeutic anticoagulation is given; remove it if unnecessary, infected or malfunctioning.
Incidental PE requires radiology confirmation and clot-burden-specific specialist review.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Pregnancy hypercoagulability

Raised procoagulant factors, reduced protein S activity, venous stasis and delivery-related endothelial injury increase VTE risk throughout pregnancy and especially postpartum.

Malignancy-driven coagulation

Tumour tissue factor, inflammatory cytokines, neutrophil traps and endothelial activation generate thrombin, while compression and immobility add stasis.

Treatment-related risk

Surgery, central venous catheters, chemotherapy, hormonal treatment, antiangiogenic agents, hospitalisation and transfusion add indication-specific thrombotic hazards.

Patient susceptibility

Previous VTE, thrombophilia, obesity, age, multiple pregnancy, infection, dehydration and comorbidity combine with pregnancy or cancer rather than acting in isolation.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Virchow triad convergence
Hypercoagulability, venous stasis and endothelial injury coexist, producing fibrin-rich deep venous clot with potential embolisation to pulmonary arteries.
2
Proximal pregnancy distribution
Pregnancy-associated DVT is often left-sided and iliofemoral because the gravid uterus and right iliac artery compress pelvic venous outflow.
3
Persistent malignant stimulus
Active tumour and systemic treatment maintain thrombin generation after the acute event, so recurrence risk can remain high beyond an ordinary three-month course.
4
Haemostasis tension
Placental, operative, mucosal and tumour bleeding risks can coexist with severe clot risk, requiring repeated adjustment rather than a fixed algorithm.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Pregnancy DVT pattern

Unilateral whole-leg swelling, left-sided symptoms and iliac, buttock or back pain suggest proximal pelvic thrombosis beyond a routine calf presentation.

Pregnancy PE pattern

Sudden dyspnoea, pleuritic pain, syncope, haemoptysis, hypoxaemia or unexplained tachycardia needs urgent objective assessment despite physiological symptom overlap.

Cancer-associated event

New limb swelling, catheter dysfunction, chest symptoms or incidental imaging filling defect may signal thrombosis during active tumour or systemic therapy.

Bleeding-prone cancer

Luminal gastrointestinal or genitourinary lesion, brain disease, thrombocytopenia, recent surgery and renal or hepatic failure increase anticoagulant harm.

Red flags requiring action

Sudden dyspnoea, syncope, hypotension, chest pain or hypoxaemia in pregnancy, postpartum or cancer is possible PE and requires urgent objective assessment rather than attribution to physiology or malignancy.
Pelvic, iliac or inferior vena cava thrombosis can present with whole-leg swelling, back, buttock or abdominal pain and may be missed by a limited proximal leg ultrasound.
Active bleeding, placenta praevia, recent intracranial disease, severe thrombocytopenia, tumour invasion, neuraxial catheter or imminent delivery profoundly alters anticoagulation timing and needs senior coordination.
Recurrent thrombosis on treatment requires adherence, dose, interactions, HIT, cancer progression and APS assessment rather than an unexamined switch to a lower dose.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
First-line pregnancy DVT imaging: compression ultrasoundFirst stepFirst line
Why
Confirm proximal lower-limb thrombosis without ionising radiation.
Interpretation and limitations
If negative with persistent high suspicion, repeat ultrasound and assess iliac veins with appropriate Doppler or cross-sectional imaging because pelvic disease may be missed.
02
Pregnancy PE imaging pathway
Why
Confirm or exclude PE without unsafe diagnostic delay.
Interpretation and limitations
Obtain chest X-ray, then choose V/Q imaging or CTPA using radiographic findings, local expertise and shared radiation discussion; image the legs first when DVT symptoms are present.
03
Cancer VTE objective imaging
Why
Define clot site and extent and distinguish recurrence from residual abnormality.
Interpretation and limitations
Use ultrasound or CTPA and compare prior images. Confirm incidental scans with an experienced radiologist, particularly isolated subsegmental or catheter-related findings.
04
Anticoagulant safety baseline
Why
Choose an agent and dose compatible with haemostatic reserve and clearance.
Interpretation and limitations
Check FBC, platelets, actual weight, Cockcroft–Gault CrCl, liver tests, bleeding site, medicines and planned procedures; repeat frequently during chemotherapy or pregnancy change.
05
Selective anti-Xa monitoring
Why
Assess LMWH exposure when ordinary predictable pharmacology is uncertain.
Interpretation and limitations
Use an agent-specific peak sample at the protocol-defined time for severe renal impairment, extremes of weight, recurrence or selected pregnancy cases; do not chase an unspecific range.
06
Recurrence and thrombocytopenia review
Why
Separate new clot, inadequate exposure, HIT, consumption and marrow toxicity.
Interpretation and limitations
Compare imaging, platelet timing, smear, coagulation, fibrinogen, cancer treatment, adherence and interactions; calculate 4Ts before HIT testing when heparin exposed.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Physiological pregnancy symptoms

Dyspnoea, tachycardia and leg oedema are common, but abrupt, unilateral, hypoxaemic or haemodynamic features require objective VTE exclusion.

Pre-eclampsia or cardiomyopathy

Hypertension, proteinuria, pulmonary oedema and postpartum heart failure can resemble PE; ECG, biomarkers and imaging define the dominant process.

Cancer progression or infection

Lymphangitic spread, pleural effusion, pneumonia, sepsis and anaemia can cause dyspnoea or tachycardia and may coexist with thrombosis.

Superficial or catheter pathology

Superficial thrombophlebitis, line infection, catheter occlusion and tumour compression cause local symptoms but require different imaging, source and anticoagulation decisions.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01Suspected pregnancy VTEAnticoagulate and image promptlyFirst stepPregnant or postpartum patient has clinical features of DVT or PE.

1Assess stability, bleeding and delivery context and begin therapeutic LMWH while arranging imaging if delay is expected and no contraindication exists.
2Use compression ultrasound for leg symptoms and a chest X-ray-guided V/Q or CTPA pathway for suspected PE.
3If confirmed, agree LMWH dose, delivery and neuraxial plan and continue through at least 6 weeks postpartum and 3 months total.

02Cancer-associated VTESelect by tumour and bleeding contextProximal DVT or PE is confirmed in active cancer.

1Assess haemodynamics, tumour site, luminal lesions, platelets, organ function, interactions, absorption, procedures and patient priorities.
2Use apixaban, rivaroxaban or LMWH according to suitability and current NICE and specialist guidance, with an exact dose and interruption plan.
3Review at 3–6 months and at every cancer transition, continuing while benefit exceeds bleeding and the malignant risk remains active.

03Delivery planningCreate one written obstetric anticoagulation planA pregnant patient on therapeutic anticoagulation approaches labour, induction or caesarean delivery.

1Coordinate obstetrics, haematology and anaesthesia, document last-dose timing, renal function, intended delivery and haemorrhage risks.
2Withhold therapeutic LMWH for the protocol interval, normally at least 24 hours before planned neuraxial anaesthesia, and instruct the patient not to inject after labour begins.
3Restart after haemostasis and neuraxial safety criteria, then complete at least 6 postpartum weeks and the minimum total course.

04Cancer thrombocytopeniaBalance acute clot against current plateletsPlatelets fall or bleeding develops during treatment of cancer-associated VTE.

1Define platelet trend, active bleeding, clot age, burden and progression risk and check DIC, HIT, sepsis and treatment cause.
2Use the agreed specialist protocol for full dose, modified dose, platelet-supported treatment or temporary withholding rather than an isolated generic threshold.
3Repeat platelets and clinical review frequently and return toward therapeutic treatment as recovery and haemostasis permit.

Key medicines and prescribing safety5 treatments · regimens, roles and cautions

First-line treatment for most pregnancy-associated DVT or PE because LMWH does not cross the placenta and has predictable subcutaneous effect.

Enoxaparin in pregnancy-associated VTE

A common therapeutic regimen is 1 mg/kg subcutaneously every 12 hours, using the weight rule in the obstetric protocol; continue for the remainder of pregnancy and at least 6 weeks postpartum, with at least 3 months total.

Adjust or monitor in renal impairment and selected weight extremes. Coordinate delivery and neuraxial timing, review platelets and bleeding and use UFH when very rapid offset is needed. Do not give with suspected HIT.

An oral option offered by NICE for many adults with active cancer-associated proximal DVT or PE when tumour, absorption and interaction context is suitable.

Apixaban for cancer-associated VTE

Give 10 mg orally twice daily for 7 days then 5 mg twice daily; after 6 months, any move to 2.5 mg twice daily must follow an individual extended-treatment decision rather than automatic reduction in active cancer.

Review luminal gastrointestinal or genitourinary lesions, thrombocytopenia, vomiting, CYP3A4/P-gp interactions, renal and liver function and procedures. Avoid during pregnancy and breastfeeding; use specialist guidance for brain tumours or very low platelets.

A single-drug oral VTE option when active cancer does not create unacceptable mucosal bleeding, interaction or absorption concerns.

Rivaroxaban for cancer-associated VTE

Give 15 mg orally twice daily with food for 21 days then 20 mg once daily with food; extended 10 mg dosing after 6 months requires a specific recurrence-versus-bleeding decision in active cancer.

Both 15 mg and 20 mg doses require food. Calculate renal function, review hepatic disease, gastrointestinal or urinary lesions and strong CYP3A4/P-gp interactions, and avoid in pregnancy and breastfeeding.

Preferred when oral absorption or interactions are unreliable, bleeding needs rapid treatment flexibility, pregnancy coexists, or tumour and platelet context makes a DOAC unsuitable.

Therapeutic LMWH in cancer

Use an exact licensed weight-based regimen such as enoxaparin 1 mg/kg subcutaneously every 12 hours; select renal adjustment and any recurrence or thrombocytopenia modification through the specialist protocol.

Monitor renal trajectory, actual weight, platelets, injection burden and HIT. Do not invent dose reductions for thrombocytopenia; match clot acuity and bleeding to the cancer-associated thrombosis protocol.

An oral anticoagulant compatible with breastfeeding and an option after delivery when DOACs are unsuitable or a vitamin K antagonist is indicated.

Warfarin postpartum

Use the anticoagulation service loading and INR-adjusted regimen postpartum when oral vitamin K antagonism is selected; overlap with therapeutic LMWH for acute VTE until the minimum heparin and therapeutic-INR criteria are met.

Do not start until postpartum haemostasis is secure. It requires frequent INR monitoring, interacts with medicines and diet and is generally avoided for routine VTE treatment during pregnancy because it crosses the placenta.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Maternal or cancer death

Massive PE causes obstructive shock, while bleeding, treatment delay and progressive malignancy complicate both recognition and rescue.

Recurrent VTE

Persistent pregnancy, postpartum or active malignant risk, missed treatment and interruption for procedures can produce propagation or embolic recurrence.

Post-thrombotic morbidity

Iliofemoral clot can cause chronic swelling, venous ulceration, pelvic collateral symptoms and reduced function long after anticoagulation ends.

Treatment-associated bleeding

Obstetric haemorrhage, thrombocytopenia, mucosal tumour bleeding, surgery, neuraxial procedures and renal accumulation can make anticoagulation hazardous.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

During pregnancy review weight, renal function, platelets, bleeding, recurrent symptoms and the delivery plan; reserve anti-Xa measurement for a defined problem rather than routine testing.
After delivery check haemostasis, haemoglobin, renal function, neuraxial catheter timing and wound status before each escalation from withheld to prophylactic or therapeutic anticoagulation.
During cancer treatment review FBC and platelets, renal and liver function, tumour bleeding, vomiting, absorption, interactions and procedures at every cycle or clinically relevant change.
At 3–6 months document cancer activity, current systemic treatment, recurrence and bleeding, prognosis and patient priorities before continuing, reducing or stopping therapy.
For a retained catheter, monitor function, infection and arm or neck symptoms and reassess removal when it is redundant, displaced, infected or anticoagulation cannot be delivered safely.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Imaging protects pregnancy

The maternal and fetal risk from untreated PE is much greater than the small radiation risk of a properly selected diagnostic study. Explain choices without creating delay.

Postpartum risk persists

Delivery ends pregnancy but not hypercoagulability. Completing at least six postpartum weeks and three months total prevents an early false stop.

Cancer is not one modifier

A pancreatic tumour with chemotherapy, a treated breast cancer and a bleeding bladder lesion have different recurrence, interaction and bleeding profiles despite the same label.

Platelets require context

A number must be interpreted with trend, active bleeding and clot age and burden. Protocol-supported transfusion or dose modification may preserve treatment during the highest-risk period.

Lines can often remain

Removing every thrombosed catheter sacrifices access and may embolise clot. Continued need, correct position, function and absence of infection guide the decision.

11Common pitfallsFrequent interpretation and management errors.

01
Do not withhold diagnostic chest imaging solely because a patient is pregnant; use the obstetric imaging pathway and explain relative exposures.
02
Do not use a negative limited leg ultrasound to dismiss persistent iliac-pattern pain and whole-leg swelling; repeat or image the pelvic veins.
03
Do not prescribe a DOAC during pregnancy or routine breastfeeding treatment without a specialist evidence-based exception.
04
Do not assume all cancer-associated VTE requires LMWH or all can take a DOAC; tumour site, platelets, interactions, absorption and patient preference decide suitability.
05
Do not stop cancer anticoagulation automatically at 3 months while disease and systemic treatment remain active; perform the planned 3–6-month review.
06
Do not use an IVC filter as a substitute for anticoagulation when anticoagulation is feasible; specify indication, retrieval date and treatment restart.